Latest News

5th December 2016

Response to NHS England announcement

NHS England yesterday announced that they will not be rolling out PrEP as a new specialised service. Instead, they will make up to £10 million available to Public Health England to enrol at least 10,000 participants over the next 3 years in a clinical trial of PrEP (

We are disappointed that PrEP will not be available on the NHS in the near future. Nonetheless, we are glad that at least 10,000 people will be offered PrEP, as even this limited availability has the potential to dramatically reduce the number of new HIV infections reported each year, when delivered as part of a comprehensive HIV prevention package.

The PROUD trial demonstrated that the offer of PrEP:

  • can attract individuals at high risk of HIV

  • can be delivered through sexual health clinics

  • dramatically reduces the risk of HIV infection

  • is cost effective when efficiently targeted towards people at risk of HIV.

Early next year we will release new evidence on long-term use of PrEP collected over the 4 years of the PROUD trial, which will provide additional insights for PrEP implementation.

The NHS England announcement claims that an additional clinical trial is necessary in order to address “significant outstanding implementation questions” around uptake, preferred dosing methods, duration of  use, HIV incidence and STI incidence. We look forward to further details about the trial design including the control group, and how these research questions will be measured.   We hope that the plan is to build on evidence from PROUD, instead of merely repeating the important work that has already been completed, and the PROUD team are willing to support the Public Health England trial team to achieve this.   

There are important outstanding questions about uptake, adherence and duration of use PrEP among populations who were not included in PROUD, and we look forward to hearing about plans to actively include heterosexual  women and men, BAME communities, and trans women and trans men in the new clinical trial.

We remain eager to hear from NHS England how they will partner with Local Authorities to commission PrEP as part of a comprehensive prevention package in the near future.

10th November 2016

Today we welcome the judgement from the Court of Appeal that confirms that NHS England has the ability to fund PrEP. The clinical evidence for PrEP is indisputable. We are confident this will result in NHS England deciding to fund PrEP and a successful discussion with local authorities  about administering PrEP. We recognise that there will be short-term cost implications until the patent for the drug ends in 2017, but this should not deter the offer of this game-changing HIV prevention option.

NHS England statement:

3rd November 2016

PROUD participants: The extra drug donated by Gilead is now in your clinics, please contact your clinic for further information.

3rd October 2016

PROUD participants:  the extra drug donated by Gilead is NOT yet in clinics. Keep in touch with your clinic to find out when it will be available.

29 July 2016

We are sorry to announce that PROUD has to close according to the plan agreed in January, which allowed for one visit after the anticipated NHS England decision in June. This decision never took place. The NHS England announcement of 21 March 2016 implied a commitment to PROUD participants that continue to need PrEP. However, it transpires that this commitment is contained within the £2M set aside for early implementer sites. Public Health England (PHE) is working, with partners, on the design of the early implementer sites but these will not be launched until 2017. Gilead is also planning a study to compare Truvada (the drug used in PROUD) to F/TAF (a new version of Truvada). The study is called DISCOVER and everyone in the study will get PrEP. DISCOVER is likely to start in the next 6 months.

In June this year we found out that NHS England had no separate plan for PROUD participants.

We wrote to Gilead with a request for a donation of drug for PROUD participants to bridge the gap between PROUD closing and the PHE/DISCOVER studies starting. Gilead is considering this request, but could not activate it until October as they won’t have approval for Truvada as PrEP in Europe until then.

It is legal in the UK to purchase drug for personal use and you can find out more about how to do this on the following websites:

If you decide to do this, please read the following article and order drug in plenty of time so that you don’t run out.

Prepster also has information on what you can do to call for increased access to PreP in the UK.

We thank the PROUD participants for taking part in a study that has accelerated access to PrEP globally, if not yet at home.

3 June 2016

In March, NHS England announced: In addition, NHS England is keen to explore how a period of further support can be offered to the participants enrolled in the PROUD study and is committed to making funding available where there is a clinical need for additional help.”

Sheena McCormack wrote to Simon Stevens for an update on how NHS England are planning to support PROUD participants access to PrEP and to date have only received the following unhelpful letter. We will continue to pursue this!

31 May 2016

Here is a further disappointing update from NHS England on commissioning and provision of Prophylaxis (PrEP) for HIV prevention:

May 2016

BHIVA-BASHH Position Statement on PrEP in the UK (second update May 2016)

The Position Statement was revised following an NHS England update on the commissioning and provision of pre-exposure prophylaxis (PrEP) for HIV prevention (

World AIDS Day announcement
1 December 2015

On this World AIDS Day of 2015 we can celebrate a year of major successes in HIV prevention.

Last week the French Ministry of Health was the first in Europe to authorise access to PrEP for populations most at risk of HIV infection. This decision was largely based on the results of the IPERGAY study who released their results in the New England Journal of Medicine today.

Read more

PROUD results published showing pre-exposure prophylaxis effectively prevents HIV

10 September 2015

Results from the PROUD study, showing a daily pill can effectively protect people from HIV infection, were published today in The Lancet. PROUD is the first study of the pre-exposure prophylaxis approach to preventing HIV to be carried out in the UK. The results show the approach could play a major role in reducing the number of new infections among men who have sex with men.

Pre-exposure prophylaxis (PrEP) is a HIV prevention strategy that involves HIV-negative people taking antiretroviral drugs to reduce the risk of becoming infected if they are exposed to the virus. The PROUD study looked at whether offering daily PrEP to men who have sex with men was an effective way to prevent HIV infection.  The results show that PrEP is highly protective, reducing the risk of infection for this group by 86%.

Read more

Study Results

24 February 2015

The PROUD study today reported that PrEP reduced the risk of HIV infection by 86% for gay and other men who have sex with men when delivered in sexual health clinics in England.

The PROUD study measured the effectiveness of daily PrEP for gay and other men who have sex with men in England.  The results released at the Conference on Retroviruses and Opportunistic Infections today indicate that PrEP is highly protective for this group, reducing the risk of infection by 86%. The researchers concluded that PrEP offers a major opportunity to curb new HIV infections in men who have sex with men in the UK.

Read more

The PROUD Study

Examining the impact on gay men of using Pre-Exposure Prophylaxis (PrEP)

What is PrEP?

PrEP (Pre-Exposure Prophylaxis) is a new way to reduce the risk of getting HIV. It involves HIV negative people taking a daily tablet that contains drugs commonly used to treat HIV.

PROUD is a two-year study to recruit volunteers across England, who will be placed at random into one of two groups. One group will use PrEP from the start of the study, and the other group will receive PrEP after 12 months.

Truvada (which contains tenofovir and emtricitabine, also called FTC) is used in this study. Truvada is already widely used and any side effects are usually mild.

Previous studies with gay men found that using PrEP almost halved HIV infections – and there were even fewer infections amongst men who took their pill every day.

Other News

PROUD trial documentary: 

The world premiere screening of the PROUD documentary took place in London on 1st July 2015. It has also been shown in Birmingham, Brighton, East London and Hamburg. Thank you to those who organised, hosted and attended these events.

Watch the PROUD documentary here:

Further screenings to be scheduled soon at various UK/international locations. Click here to see listings.

Read more

If you would like to receive updates on the development of a research agenda around PrEP including future PrEP studies and on the development of a PrEP policy in the UK, sign up to the new MRC CTU at UCL PrEP Update mailing list by sending an email to:

19 January 2014


Given that the PROUD pilot study has answered the important question of how much protection daily Truvada can offer when provided in sexual health clinics in the UK, there is no need for the planned larger clinical trial. As such, we have withdrawn our funding application to reopen the PROUD study for new recruitment.

Read more

Trial participants can now use a mobile format to complete their diary and questionnaires.           

This can be found at:


HIV charities release joint statement on PrEP

A group of the UK’s leading HIV charities have released a joint statement outlining their position on Pre-Exposure Prophylaxis (PrEP). Read more